[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine

President Donald Trump’s stock transaction filings reveal multiple purchases of Moderna ($MRNA) during March 2026, followed by a partial sale on May 18. Since those trades, the FDA's Vaccines and Related...

MRNA : 68.50 (-10.53%)
PFE : 24.27 (+0.08%)
GSK : 52.75 (+0.53%)
Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock.

Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.

TGT : 134.43 (+1.63%)
MSFT : 385.37 (+0.26%)
$SRCS : 930.47 (+0.88%)
COST : 915.96 (+0.33%)
NVS : 154.32 (-0.19%)
HLN : 9.77 (+0.62%)
GSK : 52.75 (+0.53%)
PFE : 24.27 (+0.08%)
WMT : 113.91 (+1.52%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 41.26 (-4.05%)
AZN : 172.53 (-3.34%)
MRK : 123.78 (-1.03%)
GILD : 130.10 (-3.52%)
TEM : 57.82 (-5.98%)
GSK : 52.75 (+0.53%)
ARKK : 80.42 (-1.36%)
BMY : 57.49 (-0.78%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment 1 ...

SPRO : 2.11 (-0.47%)
GSK.LN : 1,961.500 (+0.10%)
GSK : 52.75 (+0.53%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs...

SPRO : 2.11 (-0.47%)
GSK.LN : 1,961.500 (+0.10%)
GSK : 52.75 (+0.53%)
MarketBeat Week in Review – 06/08 - 06/12

Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum

NVDA : 209.96 (+3.54%)
GOOGL : 356.55 (-0.65%)
AAPL : 316.19 (-0.01%)
WING : 155.08 (-1.67%)
SPOT : 481.17 (-0.97%)
CBRL : 51.35 (+3.72%)
P : 79.66 (-1.61%)
IREN : 41.50 (-0.53%)
TSLA : 409.41 (+0.70%)
SPCX : 148.07 (-2.69%)
INTC : 109.81 (-2.43%)
NUVL : 123.89 (+0.05%)
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

RHHVF : 423.7240 (+2.39%)
NUVL : 123.89 (+0.05%)
GSK : 52.75 (+0.53%)
PFE : 24.27 (+0.08%)
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc ...

NUVL : 123.89 (+0.05%)
GSK : 52.75 (+0.53%)
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

NUVL : 123.89 (+0.05%)
RHHBY : 51.9500 (-0.13%)
GSK : 52.75 (+0.53%)
PFE : 24.27 (+0.08%)
Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.

NVDA : 209.96 (+3.54%)
AZN : 172.53 (-3.34%)
AMD : 552.74 (+1.10%)
ARM : 325.06 (-0.86%)
GSK : 52.75 (+0.53%)
TSM : 436.19 (-0.18%)

Barchart Exclusives

Wells Fargo Just Upgraded Seagate Stock. Here's Why.
Seagate stock is inching higher after Wells Fargo issued a bullish research note. Here’s how high analyst Aaron Rakers believes STX shares could fly in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.